---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034876"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:48:54.061713+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine

## Summary
- Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.
- Completed enrollment in Phase 2 START trial in early Alzheimer's; topline results expected in 2027.
- FDA Division of Psychiatry meeting anticipated by mid-2026 to discuss registrational plan for zervimesine in DLB psychosis.
- Launched expanded access program for DLB patients following a philanthropic donation.
- Appointed Dr. David Weinstein as VP of clinical development.

## SEC filing metadata
- accession: 0001104659-26-034876
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/tm269805d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034876
- JSON: https://secwatch.observer/filing/0001104659-26-034876.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034876.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.
  - Period: the year ended December 31, 2025
  - Net income: $23.5 million, or $(0.32) per basic and diluted share
  - EPS: $(0.32) per basic and diluted share
  - Result: reported results
  source text: $12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.